Home
overview
The Tissue Engineering industry is a growing Industry with the potential for dramatic improvements in medical care and medical costs. Recent developments in technology have encouraged more opportunities within the sector, and have led to emerging products and improved therapies to treat many types of disease.

Tissue Engineering will aim to highlight the current key issues in the industry and the opportunities for the future, focusing on tissue repair, replacement and regeneration. Topics covered at the conference will include organ regeneration, detailing various aspects relating to skin regeneration, heart, liver and neural transplantation therapies.

Various commercialisation issues will be covered in detail, in particular opportunities created by forming alliances, regulatory and ethical issues, commercialisation and the influence of new technology. These will be discussed both in theoretical terms and through practical current case studies.

Why should you attend this event?
This comprehensive conference is organised and produced by SMi: we specialise in providing senior executives with timely, strategic and focused up to date information. SMi conferences are leading-edge business events offering delegates the opportunity to meet senior industry and government figures and seek their advice and opinions. The conference will of course also be an ideal opportunity for you to network with a focused and appropriate audience.

Please register now to guarantee your place at this important conference

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr Alan Russell

Dr Alan Russell, Executive Director, Pittsburgh Tissue Engineering Initiative

9:10 TISSUE ENGINEERING

Dr Eugene Bell

Dr Eugene Bell, Chief Scientific Officer & Chairman, TEI Biosciences

  • TEI Biosciences has developed three technology platforms that target the challenge of reconstituting body parts.
  • TEI’s platforms focus on stem cells, signalling molecules and collagen scaffolds, including spun collagen and collagen fabrics.
  • The company has discovered a proprietary source of human stem cells.
  • It has discovered a family of tissue specific signalling molecules called Signal-plexes that induce human or mouse stem cells to adopt specific phenotypes predictibly.
  • The Company’s partner in the realms of cardiovascular and spinal orthopedic prostheses is Medtronic with whom it has a six year agreement.
  • The Company is in the process of bringing a number of 510k products to market with the expectation of entry in 2002
  • 9:40 TISSUE REPAIR, REPLACEMENT AND REGENERATION

    Dr Dale Devore

    Dr Dale Devore, Chief Scientific Officer & Senior Vice President, Research & Development, Collagenesis

  • Pathways for regenerative medicine
  • Current Biomaterials used for repair or replace damaged tissues
  • New technology approaches for regenerative medicine
  • Engineered Tissues-functional assessment and immune responses
  • 10:20 BIOENGINEERED CELLS

    Clayton Duncan

    Clayton Duncan, President & Chief Executive Officer, Incara Pharmaceuticals

  • Human Liver (Adult) stem cells
  • Avaliability
  • Preclinical results
  • Clinical precedence for liver cell transplantation
  • Clinical trial timing
  • Future gene therapy/genomics applications
  • 11:00 Morning Coffee

    11:20 IMPLANTABLE TISSUES FOR LONG-TERM PROTEIN DELIVERY

    Dr Robert Valentini

    Dr Robert Valentini, Chief Executive Officer, Cell Based Delivery

  • Recombinant Factors
  • Technology issues
  • The Future
  • 12:00 SMALL-MOLECULE REGULATED CELL THERAPY

    Dr Harvey Berger

    Dr Harvey Berger, Chairman & Chief Executive Officer, ARIAD Pharmaceuticals

  • ARGENT cell-death and cell-growth switches to control therapy
  • Positive selection of therapeutic cells
  • Regulated stem cell gene therapy
  • Treatment of graft-vs-host disease following allogeneic BMT
  • Myocardial infarction- replacing dead myocardial tissue
  • Genetic diseases- treatment for hemoglobinopathies
    Hepatic failure- Liver regeneration
  • 12:40 Networking Lunch

    13:40 MATRIX PROTEINS IN WOUND HEALING

    Dr David Amrani

    Dr David Amrani, Senior Research Director, Baxter

  • Brief history/basis of biological matrices in wound healing
  • Specific applications for use of collagens and fibrin sealants
  • New treatment for post-surgical adhesion prevention
  • Understanding the fibrin sealant-cellular combination treatment approach to wound healing
  • 14:20 CELL BASED THERAPEUTICS

    George Oram

    George Oram, President & Chief Executive Officer, Tissue Transformation Technologies

  • Autologous, Allogeneic and Cadaveric cells
  • Cell Replacement Therapies
  • Hepatocyte Transplantation
  • Pancreatic Islet Cells in Type 1 Diabetes
  • Stem Cell Applications
  • 15:00 SKIN REGENERATION

    Dr Edward Baetge

    Dr Edward Baetge, Chief Scientific Officer, Modex Therapeutics

  • Use of artificial skin to heal ulcers
  • Epidex Product
  • Adult Stem/progenitor keratinocyte culture system
  • EPIDEX Clinical experience
  • The future market
  • 15:40 Afternoon Tea

    16:00 REPAIRING SKIN WOUNDS THROUGH TISSUE REGENERATION

    Dr Ronald Hill

    Dr Ronald Hill, Vice President, Research & Development, Encelle

  • E-Matrix: Concept to Clinic
  • Using E-Matrix to treat Diabetic Foot Ulcers
  • Other Opportunities
  • 16:30 BRINGING BIOTECHNOLOGY TO ORTHOPAEDICS

    Dr Susan Long

    Dr Susan Long, Senior Director, Business Development, Genzyme Biosurgery

  • Advances in biomedical research are creating new therapeutic options for the treatment of diseased and damaged tissue
  • Technologies include gene and cell therapy, advanced biopolymers and tissue engineered products
  • As a pioneering product in bio-orthopaedics, CarticelR illustrates the challenges and opportunities for cartilage tissue engineering
  • Genzyme’s experience with Cartice and other emerging biological treatments for orthopaedics
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Professor Bader

    Professor Bader, Professor of Medical Engineering, Queen Mary, University of London

    9:10 REACTING POLYMERS WITH CELLS AND BIOMOLECULES TO CREATE BIOMOLECULAR PAVINGS

    Dr Alan Russell

    Dr Alan Russell, Executive Director, Pittsburgh Tissue Engineering Initiative

  • Do cells survive reaction with polymers
  • Do proteins survive reaction with polymers
  • Modification of pancreatic islets with stealth polymers
  • Incorporation of signal proteins into polymers
  • 9:40 OVERCOMING THE IMMUNE RESPONSE

    Dr Mary White-Scharf

    Dr Mary White-Scharf, Senior Vice President, Research, BioTransplant

  • Examining the current situation
  • Methods to induce tolerance
  • Immunological hurdles
  • 10:20 DEVELOPMENTAL BIOLOGY AND STEM CELLS IN REGENERATIVE MEDICINE

    Dr Doros Platika

    Dr Doros Platika, President & Chief Executive Officer, Curis

  • Mechanisms that govern embrionic development
  • Identifying genes and proteins and their development for therapeutic use
  • Therapy by live cells for tissue regeneration or normal physiological function
  • Tissue engineered matrices for tissue formation and repair
  • Small molecules identified from combinatorial chemistry libraries by cell based and developmental biology
  • 11:00 Morning Coffee

    11:20 INTELLIGENT POLYMER SCAFFOLDS

    Kevin Shakesheff

    Kevin Shakesheff, Chair of Tissue Engineering,University of Nottingham & Science Director, RegenTec

  • Multiple signalling types
  • Commercial opportunities in scaffold design
  • Surface engineering
  • Controlled release technologies
  • Microfabrication
  • In situ self assembly
  • 12:00 TELOMERASE, HUMAN EMBRYONIC STEM CELLS AND NUCLEAR TRANSFER

    Thomas Okarma

    Thomas Okarma, President & Chief Executive Officer, Geron Corporation

  • Penetrating the emerging field of regenerative medicine
  • Technology and business model
  • Cardiomyocytes
  • Hepatocytes
  • Neural cells
  • 12:40 Networking Lunch

    13:40 PATENT AND REGULATORY ISSUES

    Robert Barry & Dr Stuart Woods

    Robert Barry & Dr Stuart Woods, Partners, Allen & Overy

  • Recent developments affecting patentability
  • Festo Problems; Infringement issues
  • Patent strategy
  • International regulations
  • Safety and clinical efficacy
  • Improving the regulatory process
  • 14:20 COMMERCIALISATION OF TISSUE ENGINEERED PRODUCTS

    Pieter Wolters

    Pieter Wolters, Vice President & Chief Executive Officer, IsoTis N.V

  • Scaling up to produce commercially viable products
  • The commercial process
  • Technological barriers
  • Product positioning
  • What systems are suited to supporting efficient product availability
  • Storage and translation issues
  • 15:00 FROM CONCEPT TO COMMERCIALIZATION

    Dr Steven Katz

    Dr Steven Katz, Chairman & Chief Executive Officer, Ortec International

  • The early days
  • FDA Interaction
  • Effective Financing
  • Building an infrastructure
  • Transition to commercialization
  • 15:40 Afternoon Tea

    16:00 EMERGING MARKETS FOR CELL & TISSUE THERAPIES

    Dr Weaver Gaines

    Dr Weaver Gaines, Chairman & Chief Executive Officer, Ixion Biotechnologies

  • Potential applications for tissue regeneration and cellular therapy
  • Evaluation of the key market segments for application of cellular products
  • Critical ethical issues, especially regarding stem cell sources
  • Xenographic vs allogenic issues from a market perspective
  • 16:30 THE FUTURE OF TISSUE ENGINEERING

    Dr Michael Sittinger

    Dr Michael Sittinger, Associate Professor & Director, Research, BioTissue Technologies

  • Emerging products and markets
  • Genetic approaches to tissue engineering
  • How are implants retrieved at the end of their useful lives
  • Synthetic materials versus human cells seeded on scaffolds
  • Potential of morphogenetic growth factors
  • Guided tissue repair and in vivo regeneration
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.